secondary obesity

(redirected from CNS disease)
Obesity due to endocrine or other systemic disease

secondary obesity

Obesity due to endocrine or other systemic disease. See Morbid obesity, Obesity.
Secondary obesity
Congenital Alström-Hallgren syndrome, Carpenter syndrome, Cohen syndrome, Lawrence-Moon-Biedl syndrome, Prader-Willi syndrome, Vasquez syndrome
CNS disease Defects of hypophyseal-hypothalamic axis, intracranial leukemia, and other lesions
Endocrinopathies Hypothyroidism, insulinoma, Cushing syndrome, polycystic ovary disease, pituitary dwarfism
References in periodicals archive ?
Other focus programmes include disease areas such as CNS disease.
The allowed claims cover the isolated cells as well as their use in the manufacture of a drug for treating a CNS disease or disorder, selected from the group consisting of: Parkinson's, multiple sclerosis, epilepsy, amyotrophic lateral sclerosis, stroke, autoimmune encephalomyelitis, diabetic neuropathy, glaucomatous neuropathy, Alzheimer's disease and Huntingdon's disease.
This investigation highlights the importance of testing nonsterile sites when CNS disease associated with EV is suspected and CSF is negative.
The ability of the virus to cause CNS disease (neurovirulence) depends on its ability to enter the brain (neuroinvasiveness).
All children admitted in the PICU with CNS disease in the age group of 29 days to 12 years were included in the study.
A new prognosticmodel to assess the risk of CNS disease in patients with aggressive B-cell lymphoma.
CS Health Tech is an AI technology company devoted to the development of robotic rehab and training therapies for CNS disease individuals.
The PsychoGenics technology platforms integrate broad in vivo behavioural expertise with developments in robotics, computer vision and bioinformatics to assess drug candidates for potential utility across the spectrum of CNS disease indications.
For experimental human CNS disease modeling, several lines of evidence suggest that pigs, especially mini-pigs, are potentially more valuable than rodents for preclinical practice.
An improvement in MDR TB pulmonary disease occurred while CNS disease worsened in one case, highlighting the need to consider the CNS as a separate therapeutic environment [2].
The material will be used by Neuway for the conduct of GLP toxicity studies and initiation of clinical development in the treatment of Progressive Multifocal Leukoencephalopathy, a very severe neurodegenerative CNS disease. Neuway will also use its EPCs as a CNS drug delivery platform by filling them with active drug substances.